KYNTRA BIO INC.
KYNB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KYNB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KYNB
Kyntra Bio Inc. (KYNB) is a biopharmaceutical company focused on developing therapies for anemia and oncology, with commercial sales of roxadustat in Japan and Europe and a pipeline including FG-3246 in Phase 2.
Key risk: Continued operating losses
BioSniper Score
Based on 6 of 6 signals
Market Cap
$32.5M
Cash Runway
68.4 moLead Asset
EVRENZO (爱瑞卓®) / roxadustat (Approved)
Next Catalyst
Phase3_Topline · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 128 clinical trials · 15 catalysts for KYNTRA BIO INC..
Kyntra Bio Inc. (KYNB) is a biopharmaceutical company focused on developing therapies for anemia and oncology, with commercial sales of roxadustat in Japan and Europe and a pipeline including FG-3246 in Phase 2.
- Cash and equivalents of $50.6M as of 2026-06-30 [sec].
- Net income of $12.0M for the period ended 2026-06-30 [sec].
- Commercial sales of roxadustat in Japan and Europe generate revenue [sec_mda · as of 2026-08-13].
- FG-3246 is in Phase 2 clinical development [sec_mda · as of 2026-05-12].
- The company has incurred approximately $3.3 billion in cumulative R&D expenses through December 31, 2025 [sec_mda · as of 2026-03-16].
What works
- Kyntra Bio has a commercial product, roxadustat, generating revenue in Japan and Europe [sec_mda · as of 2026-08-13].
- The company successfully monetized its China business for $220M, exceeding expectations and repaying debt [sec · filed 2026-04-27].
- Research and development expenses have decreased due to a cost reduction plan implemented in the U.S. in Q3 2024 [sec_mda · as of 2026-03-16].
What to weigh
- The company anticipates continued losses for the foreseeable future despite roxadustat revenue [sec_mda · as of 2026-08-13].
- Substantial additional funding will be needed to support ongoing operations and development [sec_mda · as of 2026-03-16].
- Cumulative R&D expenses total approximately $3.3 billion, with no guarantee of future product success [sec_mda · as of 2026-03-16].
- The company is subject to all risks associated with developing and commercializing novel therapeutics [sec_mda · as of 2026-03-16].
From the filings
Quoted directly from source documents.
Revenue from roxadustat in Japan and Europe
“We generate revenue from commercial sales of roxadustat product in Japan and Europe.”
SEC MD&A · August 13, 2026
Cumulative R&D expenses through December 31, 2025
“Since inception and through December 31, 2025, we have incurred a total of approximately $3.3 billion in research and development expenses”
SEC MD&A · March 16, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Topline — ProBio — Topline data from the Phase 3 ProBio study in metastatic cancer will be reported.
- 2027-09-01 · Phase3_Topline · enzalutamide — CASPAR — Topline data from the Phase 3 CASPAR trial of enzalutamide and rucaparib in first-line metastatic disease will be reported.
- 2027-12-01 · Phase3_Topline — Apa/Enza Short Study — Topline data from the Phase 3 study of shortened androgen receptor signaling agent duration will be reported.
- 2027-12-15 · Phase3_Topline · jnt-517 — Topline data from the Phase 3 double-blind, randomized study of JNT-517 will be reported.
Risks & what to watch (4)›
Key risks
- Continued operating losses — The company expects to continue generating losses for the foreseeable future despite roxadustat revenue [sec_mda · as of 2026-08-13].
- Need for additional funding — Substantial additional funding will be required to support ongoing operations and development [sec_mda · as of 2026-03-16].
- Clinical development risks — The company faces all risks inherent in developing and commercializing novel therapeutics, including unforeseen delays and expenses [sec_mda · as of 2026-03-16].
- Dependence on pipeline success — No guarantee that sufficient funds will be available to fund development through commercialization [sec_mda · as of 2026-08-13].
What to watch
- Phase 3 topline results for ProBio study expected December 2026 [upcoming catalysts].
- Phase 3 topline results for CASPAR trial (enzalutamide + rucaparib) expected September 2027 [upcoming catalysts].
- Phase 3 topline results for Apa/Enza Short study expected December 2027 [upcoming catalysts].
- Phase 3 topline results for JNT-517 study expected December 2027 [upcoming catalysts].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run KYNTRA BIO INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KYNTRA BIO INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
68.4 months
OCF -$4M · Net income $12M
Lead: Approved
4 candidates
15 upcoming, next in ~93d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$7.5M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 400,000 | $2.7M |
| vanguard capital management llc | 313,214 | $2.1M |
| susquehanna international group, llp | 89,400 | $606K |
| blackrock, inc. | 84,331 | $572K |
| two sigma investments, lp | 49,511 | $336K |
| geode capital management, llc | 45,998 | $312K |
| renaissance technologies llc | 27,481 | $186K |
| vanguard fiduciary trust co | 23,942 | $162K |
| birchview capital, lp | 22,566 | $153K |
| state street corp | 20,284 | $138K |
Showing top 10 of 31 institutional holders of KYNTRA BIO INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 2.9%
- Days to cover
- 3.2
- Shares short
- 113,876
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KYNB short interestGovernance
Frequently asked questions
What is the AI investment thesis for KYNTRA BIO INC.?
Kyntra Bio Inc. (KYNB) is a biopharmaceutical company focused on developing therapies for anemia and oncology, with commercial sales of roxadustat in Japan and Europe and a pipeline including FG-3246 in Phase 2.
What is KYNTRA BIO INC.'s lead drug candidate?
KYNTRA BIO INC.'s most advanced tracked candidate is EVRENZO (爱瑞卓®) / roxadustat (Approved) for Myelodysplastic Syndromes.
What is KYNTRA BIO INC.'s next catalyst?
KYNTRA BIO INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metasta" — expected December 1, 2026.
Who is the CEO of KYNTRA BIO INC.?
Mr. Thane Wettig is the chief executive officer of KYNTRA BIO INC. (KYNB).
Where is KYNTRA BIO INC. headquartered?
KYNTRA BIO INC. (KYNB) is headquartered in San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.